Nasdaq · Biotech stocks database
AAPG (Ascentage Pharma Group International) stock: $15.06, $1.41B market cap, $170.8M cash, $1.48B EV, $1.53B fully diluted market cap. Next expected readout: Dec-26. Lead program: lisaftoclax (CLL/SLL), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $170.8M |
|---|---|
| Debt | $248.6M |
| Net cash | -$77.8M |
| Enterprise value | $1,483.4M |
| Basic shares | 93.3M shares |
| Fully diluted shares | 101.5M shares |
| Fully diluted market cap | $1,528.8M |
| Cash per share | $1.83 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Loading AAPG daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Now - Sep 22, 2026 | Olverembatinib 20mg | Phase 1 | Pharmacokinetic; Olverembatinib | — |
| Jan 12 - Feb 23 | APG2575 | Phase 2 | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | — |
| Feb 11 - Mar 25 | lisaftoclax | Phase 3 | CLL/SLL | — |
| May 12 - Jun 23 | Olverembatinib | Phase 3 | GIST | — |
| Jun 12 - Jul 24 | APG -2449 | Phase 1 | Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid Tumor | — |
| Jul 13 - Aug 24 | APG-115 | Phase 1/2 | Neuroblastoma; Solid Tumor | — |
| Aug 11 - Sep 22 | olverembatinib | Phase 3 | Chronic Myeloid Leukemia; CML; CML, Chronic Phase | — |
| Sep 12 - Oct 24 | Lisaftoclax (APG-2575) | Phase 3 | CLL/SLL | — |
| Jan 12 - Feb 23 | HQP1351 | Phase 1 | Gastrointestinal Stromal Tumor (GIST); Solid Tumor, Adult | — |
| Jan 12 - Feb 23 | APG-2449 | Phase 1 | Advanced Solid Cancer; Non Small Cell Lung Cancer; Esophageal Cancer | — |
| Feb 11 - Mar 24 | Olverembatinib | Phase 3 | Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | — |
| Feb 11 - Mar 24 | APG-5918 | Phase 1 | Anemia | — |
| Jul 6 - Aug 17 | APG-2575(Lisaftoclax ) | Phase 3 | Acute Myeloid Leukemia | — |
| Oct 13 - Nov 24 | Lisaftoclax (APG-2575) | Phase 1/2 | Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy | — |
| Jul 13 - Aug 24 | Lisaftoclax (APG-2575) | Phase 3 | Higher-risk Myelodysplastic Syndrome | — |
| Jan 12 - Feb 23 | APG-3288 | Phase 1 | Relapsed/Refractory Hematological Malignancies; Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leu; Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Ri | — |
| Feb 7 - Mar 21 | Ascentage Pharma HQP1351 bioavailable inhibitor | Phase 1 | Leukemia, Myeloid, Chronic; Myeloid Leukemia; Chronic Myeloid Leukemia | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.